An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This multi-center, observational study will evaluate the use in clinical practice and efficacy of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the approved label will be followed for 6 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with rheumatoid arthritis initiating treatment with RoActemra/Actemra
Adult patients, >/= 18 years of age
Moderate to severe rheumatoid arthritis , according to the revised ACR criteria
Patients initiated on RoActemra/Actemra treatment (in accordance with the local label) on their treating physicians decision
RoActemra/Actemra treatment more than 8 weeks prior to enrolment visit
Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use
Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
History of autoimmune disease or of any joint inflammatory disease other than RA